{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:01:49Z","timestamp":1761742909890,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,8,1]],"date-time":"2006-08-01T00:00:00Z","timestamp":1154390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2006,8]]},"DOI":"10.1016\/j.hoc.2006.03.002","type":"journal-article","created":{"date-parts":[[2007,1,10]],"date-time":"2007-01-10T10:09:23Z","timestamp":1168423763000},"page":"797-809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Epidemiology of Prostate Cancer\u2014with a Focus on Nonsteroidal Anti-inflammatory Drugs"],"prefix":"10.1016","volume":"20","author":[{"given":"June M.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Feraco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Shuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Hern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5 Pt 2","key":"10.1016\/j.hoc.2006.03.002_bib1","first-page":"S13","article-title":"The relative impact and future burden of prostate cancer in the United States","volume":"172","author":"Chan","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.hoc.2006.03.002_bib2","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3","article-title":"Prostate carcinoma incidence and patient mortality: the effects of screening and early detection","volume":"80","author":"Brawley","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2006.03.002_bib3","unstructured":"Penson DF, Chan JM. Prostate cancer. Urological Diseases of America; in press."},{"key":"10.1016\/j.hoc.2006.03.002_bib4","doi-asserted-by":"crossref","first-page":"8152","DOI":"10.1200\/JCO.2005.03.1492","article-title":"Role of diet in prostate cancer development and progression","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2006.03.002_bib5","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/0008-5472.CAN-03-2422","article-title":"Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model","volume":"64","author":"Gupta","year":"2004","journal-title":"Cancer Res"},{"issue":"10 Pt 1","key":"10.1016\/j.hoc.2006.03.002_bib6","first-page":"1108","article-title":"Aspirin use in relation to risk of prostate cancer","volume":"11","author":"Leitzmann","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.hoc.2006.03.002_bib7","series-title":"Eicosanoids and other bioactive lipids in cancer inflammation and radiation injury 3","first-page":"163","article-title":"Up-regulation of cyclooxygenase-2 by product-prostaglandin E2","author":"Tjandrawinata","year":"1997"},{"key":"10.1016\/j.hoc.2006.03.002_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ijc.2910570208","article-title":"Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors","volume":"57","author":"Chaudry","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.hoc.2006.03.002_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/carcin\/22.5.701","article-title":"Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells","volume":"22","author":"Hughes-Fulford","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.hoc.2006.03.002_bib10","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/carcin\/bgi112","article-title":"Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells","volume":"26","author":"Hughes-Fulford","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.hoc.2006.03.002_bib11","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1074\/jbc.274.16.10911","article-title":"Inhibition of cyclooxygenase-2 gene expression by p53","volume":"274","author":"Subbaramaiah","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hoc.2006.03.002_bib12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/carcin\/bgh176","article-title":"Age-associated changes in the expression pattern of cyclooxygenase-2 and related apoptotic markers in the cancer susceptible region of rat prostate","volume":"25","author":"Badawi","year":"2004","journal-title":"Carcinogenesis"},{"issue":"24","key":"10.1016\/j.hoc.2006.03.002_bib13","first-page":"8617","article-title":"Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma","volume":"61","author":"Zha","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2006.03.002_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00006676-200301000-00007","article-title":"The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2","volume":"26","author":"Eibl","year":"2003","journal-title":"Pancreas"},{"key":"10.1016\/j.hoc.2006.03.002_bib15","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bcp.2003.12.014","article-title":"Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells","volume":"67","author":"Maier","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.hoc.2006.03.002_bib16","doi-asserted-by":"crossref","first-page":"49617","DOI":"10.1074\/jbc.M408796200","article-title":"Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase\/AKT\/GSK-3beta pathway","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hoc.2006.03.002_bib17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.bjc.6601416","article-title":"Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis","volume":"90","author":"Mahmud","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.hoc.2006.03.002_bib18","first-page":"559","article-title":"Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade","volume":"13","author":"Harris","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.hoc.2006.03.002_bib19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1464-410X.2004.04601.x","article-title":"A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy","volume":"93","author":"Pruthi","year":"2004","journal-title":"Br J Urol Int"},{"key":"10.1016\/j.hoc.2006.03.002_bib20","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/0008-5472.982.65.3","article-title":"Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor","volume":"65","author":"Eibl","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.hoc.2006.03.002_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/01.CIR.95.1.252","article-title":"Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture","volume":"95","author":"Barrett-Connor","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2006.03.002_bib22","unstructured":"Murray CJ, Lopez AD. Global Health Statistics. Harvard: World Health Organization; 1996. Available at: http:\/\/www.hup.harvard.edu\/catalog\/MURGLH.html?show=contents."},{"key":"10.1016\/j.hoc.2006.03.002_bib23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.hoc.2006.03.002_bib24","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","article-title":"An update on aspirin in the primary prevention of cardiovascular disease","volume":"163","author":"Eidelman","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib25","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.57.3.326","article-title":"Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses","volume":"57","author":"Hart","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.hoc.2006.03.002_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-136-2-200201150-00016","article-title":"Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force","volume":"136","author":"Hayden","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jama.287.3.337","article-title":"Recent patterns of medication use in the ambulatory adult population of the United States. The Slone Survey","volume":"287","author":"Kaufman","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2006.03.002_bib28","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJM200009213431202","article-title":"Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding","volume":"343","author":"Lanas","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.hoc.2006.03.002_bib30","article-title":"Long-term aspirin use and mortality among women","author":"Chan","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hoc.2006.03.002_bib31","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ehj.2003.10.013","article-title":"Expert consensus document on the use of antiplatelet agents: the Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology","volume":"25","author":"Patrono","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hoc.2006.03.002_bib32","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib33","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial investigators","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib34","unstructured":"Merck announces voluntary worldwide withdrawal of Vioxx. September 30, 2004. Available at: http:\/\/www.vioxx.com\/rofecoxib\/vioxx\/consumer\/index.jsp."},{"key":"10.1016\/j.hoc.2006.03.002_bib35","first-page":"S1758","article-title":"Etoricoxib cardiovascular safety summary","volume":"108","author":"Curtis","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.hoc.2006.03.002_bib36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2006.03.002_bib37","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa050330","article-title":"Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery","volume":"352","author":"Nussmeier","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib38","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0022-5223(03)00125-9","article-title":"Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery","volume":"125","author":"Ott","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.hoc.2006.03.002_bib39","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib40","unstructured":"Pfizer statement on new information regarding cardiovascular safety of Celebrex. December 17, 2004. Available at: www.pfizer.com\/are\/investors_releases\/2004pr\/mn_2004_1217.cfm."},{"key":"10.1016\/j.hoc.2006.03.002_bib41","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1742-7843.2006.pto_302.x","article-title":"Non-steroidal anti-inflammatory drugs and the risk of acute myocardial infarction","volume":"98","author":"Hern\u00e1ndez-D\u00edaz","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.hoc.2006.03.002_bib42","doi-asserted-by":"crossref","first-page":"234S","DOI":"10.1378\/chest.126.3_suppl.234S","article-title":"Platelet-active drugs: the relationships among dose, effectiveness, and side effects","volume":"126","author":"Patrono","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.hoc.2006.03.002_bib43","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.1994.03520100043031","article-title":"Initiation of antihypertensive treatment during non-steroidal antiinflammatory drug therapy","volume":"272","author":"Gurwitz","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2006.03.002_bib44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-199717050-00001","article-title":"NSAIDs and increased blood pressure: what is the clinical significance","volume":"17","author":"Johnson","year":"1997","journal-title":"Drug Saf"},{"key":"10.1016\/j.hoc.2006.03.002_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"Fitzgerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib46","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1161\/01.STR.0000174189.81153.85","article-title":"Risk of hemorrhagic stroke with aspirin use: an update","volume":"36","author":"Gorelick","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.hoc.2006.03.002_bib47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0895-4356(01)00461-9","article-title":"Incidence of serious upper gastrointestinal bleeding\/perforation in the general population: review of epidemiologic studies","volume":"55","author":"Hern\u00e1ndez-D\u00edaz","year":"2002","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.hoc.2006.03.002_bib48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies","volume":"52","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hoc.2006.03.002_bib49","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/archinte.160.14.2093","article-title":"Overview of epidemiological studies published in the nineties on the association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed\/perforation","volume":"160","author":"Hern\u00e1ndez-D\u00edaz","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib50","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2006.03.002_bib51","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study, a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2006.03.002_bib52","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00228-004-0813-5","article-title":"The French Network of Regional Pharmacovigilance Centres. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case\/non-case study from the French Pharmacovigilance Database","volume":"60","author":"Lugardon","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.hoc.2006.03.002_bib53","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.52.9.1265","article-title":"Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs","volume":"52","author":"MacDonald","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.hoc.2006.03.002_bib54","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/bmj.325.7365.624","article-title":"Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs","volume":"325","author":"Mamdani","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.hoc.2006.03.002_bib55","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1365-2036.2004.01913.x","article-title":"COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study","volume":"19","author":"Norgard","year":"2004","journal-title":"Aliment Phasmacol Ther"},{"key":"10.1016\/j.hoc.2006.03.002_bib56","first-page":"S233","article-title":"Gastrointestinal safety of rofecoxib and celecoxib versus NSAIDs among patients on low dose aspirin","volume":"13","author":"Rahme","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.hoc.2006.03.002_bib57","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1001\/archinte.163.17.2006","article-title":"An update on aspirin in the primary prevention of cardiovascular disease","volume":"163","author":"Eidelman","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib58","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJM199305063281805","article-title":"Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis","volume":"328","author":"Giardiello","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib59","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","article-title":"The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis","volume":"342","author":"Steinbach","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2006.03.002_bib60","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.294.8.914","article-title":"Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer","volume":"294","author":"Chan","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2006.03.002_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2407-3-28","article-title":"Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis","volume":"3","author":"Gonzalez-Perez","year":"2003","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2006.03.002_bib62","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/jnci\/94.15.1168","article-title":"Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer","volume":"94","author":"Anderson","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2006.03.002_bib63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/djh001","article-title":"A prospective study of aspirin use and the risk of pancreatic cancer in women","volume":"96","author":"Schernhammer","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hoc.2006.03.002_bib64","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1532-5415.2004.52054.x","article-title":"The relationship between a dementia diagnosis, chronic illness, medicare expenditures, and hospital use","volume":"52","author":"Bynum","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.hoc.2006.03.002_bib65","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bmj.327.7407.128","article-title":"Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies","volume":"327","author":"Etminan","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.hoc.2006.03.002_bib66","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2006.03.002_bib67","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.wco.0000170951.08924.3d","article-title":"Genetics of Parkinson's disease","volume":"18","author":"Gasser","year":"2005","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"10.1016\/j.hoc.2006.03.002_bib68","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.20682","article-title":"Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease","volume":"58","author":"Chen","year":"2005","journal-title":"Ann Neurol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858806000554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858806000554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:47:38Z","timestamp":1760183258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858806000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["S0889858806000554"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2006.03.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Epidemiology of Prostate Cancer\u2014with a Focus on Nonsteroidal Anti-inflammatory Drugs","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2006.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}